These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34080768)

  • 1. Atypical, severe hypertrophic cardiomyopathy in a newborn presenting Noonan syndrome harboring a recurrent heterozygous MRAS variant.
    Pires LVL; Bordim RA; Maciel MBR; Tanaka ACS; Yamamoto GL; Honjo RS; Kim CA; Bertola DR
    Am J Med Genet A; 2021 Oct; 185(10):3099-3103. PubMed ID: 34080768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating MRAS mutations cause Noonan syndrome associated with hypertrophic cardiomyopathy.
    Motta M; Sagi-Dain L; Krumbach OHF; Hahn A; Peleg A; German A; Lissewski C; Coppola S; Pantaleoni F; Kocherscheid L; Altmüller F; Schanze D; Logeswaran T; Chahrokh-Zadeh S; Munzig A; Nakhaei-Rad S; Cavé H; Ahmadian MR; Tartaglia M; Zenker M
    Hum Mol Genet; 2020 Jul; 29(11):1772-1783. PubMed ID: 31108500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophic cardiomyopathy in Noonan syndrome.
    Nishikawa T; Ishiyama S; Shimojo T; Takeda K; Kasajima T; Momma K
    Acta Paediatr Jpn; 1996 Feb; 38(1):91-8. PubMed ID: 8992870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of MRAS-related Noonan syndrome: Evidence of mild adult-onset left ventricular hypertrophy and neuropsychiatric features.
    Priolo M; Mancini C; Radio FC; Chiriatti L; Ciolfi A; Cappelletti C; Cordeddu V; Pintomalli L; Brusco A; Mammi C; Tartaglia M
    Am J Med Genet C Semin Med Genet; 2023 Jun; 193(2):160-166. PubMed ID: 36734411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Phenotype and Gene Mutations in RASopathies.
    Faienza MF; Meliota G; Mentino D; Ficarella R; Gentile M; Vairo U; D'amato G
    Genes (Basel); 2024 Aug; 15(8):. PubMed ID: 39202376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results.
    Calcagni G; Limongelli G; D'Ambrosio A; Gesualdo F; Digilio MC; Baban A; Albanese SB; Versacci P; De Luca E; Ferrero GB; Baldassarre G; Agnoletti G; Banaudi E; Marek J; Kaski JP; Tuo G; Russo MG; Pacileo G; Milanesi O; Messina D; Marasini M; Cairello F; Formigari R; Brighenti M; Dallapiccola B; Tartaglia M; Marino B
    Int J Cardiol; 2017 Oct; 245():92-98. PubMed ID: 28768581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
    Aoki Y; Niihori T; Banjo T; Okamoto N; Mizuno S; Kurosawa K; Ogata T; Takada F; Yano M; Ando T; Hoshika T; Barnett C; Ohashi H; Kawame H; Hasegawa T; Okutani T; Nagashima T; Hasegawa S; Funayama R; Nagashima T; Nakayama K; Inoue S; Watanabe Y; Ogura T; Matsubara Y
    Am J Hum Genet; 2013 Jul; 93(1):173-80. PubMed ID: 23791108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noonan syndrome: a clinical description emphasizing the cardiac findings.
    Noonan J; O'Connor W
    Acta Paediatr Jpn; 1996 Feb; 38(1):76-83. PubMed ID: 8992867
    [No Abstract]   [Full Text] [Related]  

  • 9. Genotype and phenotype in patients with Noonan syndrome and a RIT1 mutation.
    Kouz K; Lissewski C; Spranger S; Mitter D; Riess A; Lopez-Gonzalez V; Lüttgen S; Aydin H; von Deimling F; Evers C; Hahn A; Hempel M; Issa U; Kahlert AK; Lieb A; Villavicencio-Lorini P; Ballesta-Martinez MJ; Nampoothiri S; Ovens-Raeder A; Puchmajerová A; Satanovskij R; Seidel H; Unkelbach S; Zabel B; Kutsche K; Zenker M
    Genet Med; 2016 Dec; 18(12):1226-1234. PubMed ID: 27101134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.
    Uludağ Alkaya D; Lissewski C; Yeşil G; Zenker M; Tüysüz B
    Am J Med Genet A; 2021 Dec; 185(12):3623-3633. PubMed ID: 34184824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic landscape of RASopathies in Chinese: Three decades' experience in Hong Kong.
    Yu KPT; Luk HM; Leung GKC; Mak CCY; Cheng SSW; Hau EWL; Chan DKH; Lam STS; Tong TMF; Chung BHY; Lo IFM
    Am J Med Genet C Semin Med Genet; 2019 Jun; 181(2):208-217. PubMed ID: 30896080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Noonan syndrome phenotype associated with a germline Q71R MRAS variant: a recurrent substitution in RAS homologs in various cancers.
    Suzuki H; Takenouchi T; Uehara T; Takasago S; Ihara S; Yoshihashi H; Kosaki K
    Am J Med Genet A; 2019 Aug; 179(8):1628-1630. PubMed ID: 31173466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a genetically-modified induced pluripotent stem cell line harboring a Noonan syndrome-associated gene variant MRAS p.G23V.
    Busley AV; Cyganek L
    Stem Cell Res; 2023 Jun; 69():103108. PubMed ID: 37141804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of
    Higgins EM; Bos JM; Mason-Suares H; Tester DJ; Ackerman JP; MacRae CA; Sol-Church K; Gripp KW; Urrutia R; Ackerman MJ
    JCI Insight; 2017 Mar; 2(5):e91225. PubMed ID: 28289718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
    Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
    J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management.
    Lioncino M; Monda E; Verrillo F; Moscarella E; Calcagni G; Drago F; Marino B; Digilio MC; Putotto C; Calabrò P; Russo MG; Roberts AE; Gelb BD; Tartaglia M; Limongelli G
    Heart Fail Clin; 2022 Jan; 18(1):19-29. PubMed ID: 34776080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel heterozygous RIT1 mutation in a patient with Noonan syndrome, leukopenia, and transient myeloproliferation-a review of the literature.
    Nemcikova M; Vejvalkova S; Fencl F; Sukova M; Krepelova A
    Eur J Pediatr; 2016 Apr; 175(4):587-92. PubMed ID: 26518681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
    Yagasaki H; Nakane T; Hasebe Y; Watanabe A; Kise H; Toda T; Koizumi K; Hoshiai M; Sugita K
    Am J Med Genet A; 2015 Dec; 167A(12):3144-7. PubMed ID: 26286251
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Higgins EM; Bos JM; Dotzler SM; John Kim CS; Ackerman MJ
    Circ Genom Precis Med; 2019 Nov; 12(11):e002648. PubMed ID: 31638832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.